Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: Experience in 81 patients

A. Baars, A. M E Claessen, A. J M Van den Eertwegh, H. E. Gall, A. G M Stam, S. Meijer, G. Giaccone, C. J L M Meijer, R. J. Scheper, J. Wagstaff, J. B. Vermorken, H. M. Pinedo

Research output: Contribution to journalArticle

Abstract

Background: Currently there is no standard adjuvant treatment following surgical resection of metastatic melanoma. We investigated whether surgery followed by autologous tumor cell-BCG vaccination was beneficial for malignant melanoma patients. In this study we focus on the prognostic value of DTH response following vaccination therapy. Patients and methods: Eighty-one patients with AJCC stage III and IV melanoma were selected. Whenever feasible, radical metastasectomy was performed. ASI was initiated by the administration of three weekly intra-cutaneous vaccinations with l07 irradiated autologous tumor cells, starting four weeks after surgery. Depending on the size of DTH response to the first three injections, subsequent vaccinations were planned. The first two vaccines also contained l07 BCG organisms as an immune stimulatory adjuvant. Results: Induration as well as erythema correlated strongly with survival (P <0.0001 and P = 0.0004). After radical metastasectomy in stage III melanoma patients a five-year survival of 48% was observed. In stage IV disease, a five-year survival of 34% was seen, after radical surgery had been performed. When macroscopic disease was present at start of vaccination treatment, no clinical responses occurred. Apart from transient skin ulceration at the site of BCG-containing vaccinations, no serious side effects were observed. Conclusions: This study shows that large-scale preparation of autologous melanoma cell vaccines is feasible, while vaccination results in DTH responses that correlate significantly with survival. ASI seemed to be beneficial in stage III and stage IV melanoma when given in the adjuvant setting, while causing only very mild side effects.

Original languageEnglish (US)
Pages (from-to)965-970
Number of pages6
JournalAnnals of Oncology
Volume11
Issue number8
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Skin Tests
Melanoma
Vaccination
Survival
Mycobacterium bovis
Neoplasms
Metastasectomy
Vaccines
Skin
Erythema
Therapeutics
Injections

Keywords

  • Active specific immunotherapy (ASI)
  • Autologous tumor cell vaccines
  • Delayed type hypersensitivity (DTH)
  • Melanoma
  • Metastasectomy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Baars, A., Claessen, A. M. E., Van den Eertwegh, A. J. M., Gall, H. E., Stam, A. G. M., Meijer, S., ... Pinedo, H. M. (2000). Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: Experience in 81 patients. Annals of Oncology, 11(8), 965-970. https://doi.org/10.1023/A:1008363601515

Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma : Experience in 81 patients. / Baars, A.; Claessen, A. M E; Van den Eertwegh, A. J M; Gall, H. E.; Stam, A. G M; Meijer, S.; Giaccone, G.; Meijer, C. J L M; Scheper, R. J.; Wagstaff, J.; Vermorken, J. B.; Pinedo, H. M.

In: Annals of Oncology, Vol. 11, No. 8, 2000, p. 965-970.

Research output: Contribution to journalArticle

Baars, A, Claessen, AME, Van den Eertwegh, AJM, Gall, HE, Stam, AGM, Meijer, S, Giaccone, G, Meijer, CJLM, Scheper, RJ, Wagstaff, J, Vermorken, JB & Pinedo, HM 2000, 'Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: Experience in 81 patients', Annals of Oncology, vol. 11, no. 8, pp. 965-970. https://doi.org/10.1023/A:1008363601515
Baars, A. ; Claessen, A. M E ; Van den Eertwegh, A. J M ; Gall, H. E. ; Stam, A. G M ; Meijer, S. ; Giaccone, G. ; Meijer, C. J L M ; Scheper, R. J. ; Wagstaff, J. ; Vermorken, J. B. ; Pinedo, H. M. / Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma : Experience in 81 patients. In: Annals of Oncology. 2000 ; Vol. 11, No. 8. pp. 965-970.
@article{1f4c1f13111f4dd990471e33d0cea5b5,
title = "Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: Experience in 81 patients",
abstract = "Background: Currently there is no standard adjuvant treatment following surgical resection of metastatic melanoma. We investigated whether surgery followed by autologous tumor cell-BCG vaccination was beneficial for malignant melanoma patients. In this study we focus on the prognostic value of DTH response following vaccination therapy. Patients and methods: Eighty-one patients with AJCC stage III and IV melanoma were selected. Whenever feasible, radical metastasectomy was performed. ASI was initiated by the administration of three weekly intra-cutaneous vaccinations with l07 irradiated autologous tumor cells, starting four weeks after surgery. Depending on the size of DTH response to the first three injections, subsequent vaccinations were planned. The first two vaccines also contained l07 BCG organisms as an immune stimulatory adjuvant. Results: Induration as well as erythema correlated strongly with survival (P <0.0001 and P = 0.0004). After radical metastasectomy in stage III melanoma patients a five-year survival of 48{\%} was observed. In stage IV disease, a five-year survival of 34{\%} was seen, after radical surgery had been performed. When macroscopic disease was present at start of vaccination treatment, no clinical responses occurred. Apart from transient skin ulceration at the site of BCG-containing vaccinations, no serious side effects were observed. Conclusions: This study shows that large-scale preparation of autologous melanoma cell vaccines is feasible, while vaccination results in DTH responses that correlate significantly with survival. ASI seemed to be beneficial in stage III and stage IV melanoma when given in the adjuvant setting, while causing only very mild side effects.",
keywords = "Active specific immunotherapy (ASI), Autologous tumor cell vaccines, Delayed type hypersensitivity (DTH), Melanoma, Metastasectomy",
author = "A. Baars and Claessen, {A. M E} and {Van den Eertwegh}, {A. J M} and Gall, {H. E.} and Stam, {A. G M} and S. Meijer and G. Giaccone and Meijer, {C. J L M} and Scheper, {R. J.} and J. Wagstaff and Vermorken, {J. B.} and Pinedo, {H. M.}",
year = "2000",
doi = "10.1023/A:1008363601515",
language = "English (US)",
volume = "11",
pages = "965--970",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma

T2 - Experience in 81 patients

AU - Baars, A.

AU - Claessen, A. M E

AU - Van den Eertwegh, A. J M

AU - Gall, H. E.

AU - Stam, A. G M

AU - Meijer, S.

AU - Giaccone, G.

AU - Meijer, C. J L M

AU - Scheper, R. J.

AU - Wagstaff, J.

AU - Vermorken, J. B.

AU - Pinedo, H. M.

PY - 2000

Y1 - 2000

N2 - Background: Currently there is no standard adjuvant treatment following surgical resection of metastatic melanoma. We investigated whether surgery followed by autologous tumor cell-BCG vaccination was beneficial for malignant melanoma patients. In this study we focus on the prognostic value of DTH response following vaccination therapy. Patients and methods: Eighty-one patients with AJCC stage III and IV melanoma were selected. Whenever feasible, radical metastasectomy was performed. ASI was initiated by the administration of three weekly intra-cutaneous vaccinations with l07 irradiated autologous tumor cells, starting four weeks after surgery. Depending on the size of DTH response to the first three injections, subsequent vaccinations were planned. The first two vaccines also contained l07 BCG organisms as an immune stimulatory adjuvant. Results: Induration as well as erythema correlated strongly with survival (P <0.0001 and P = 0.0004). After radical metastasectomy in stage III melanoma patients a five-year survival of 48% was observed. In stage IV disease, a five-year survival of 34% was seen, after radical surgery had been performed. When macroscopic disease was present at start of vaccination treatment, no clinical responses occurred. Apart from transient skin ulceration at the site of BCG-containing vaccinations, no serious side effects were observed. Conclusions: This study shows that large-scale preparation of autologous melanoma cell vaccines is feasible, while vaccination results in DTH responses that correlate significantly with survival. ASI seemed to be beneficial in stage III and stage IV melanoma when given in the adjuvant setting, while causing only very mild side effects.

AB - Background: Currently there is no standard adjuvant treatment following surgical resection of metastatic melanoma. We investigated whether surgery followed by autologous tumor cell-BCG vaccination was beneficial for malignant melanoma patients. In this study we focus on the prognostic value of DTH response following vaccination therapy. Patients and methods: Eighty-one patients with AJCC stage III and IV melanoma were selected. Whenever feasible, radical metastasectomy was performed. ASI was initiated by the administration of three weekly intra-cutaneous vaccinations with l07 irradiated autologous tumor cells, starting four weeks after surgery. Depending on the size of DTH response to the first three injections, subsequent vaccinations were planned. The first two vaccines also contained l07 BCG organisms as an immune stimulatory adjuvant. Results: Induration as well as erythema correlated strongly with survival (P <0.0001 and P = 0.0004). After radical metastasectomy in stage III melanoma patients a five-year survival of 48% was observed. In stage IV disease, a five-year survival of 34% was seen, after radical surgery had been performed. When macroscopic disease was present at start of vaccination treatment, no clinical responses occurred. Apart from transient skin ulceration at the site of BCG-containing vaccinations, no serious side effects were observed. Conclusions: This study shows that large-scale preparation of autologous melanoma cell vaccines is feasible, while vaccination results in DTH responses that correlate significantly with survival. ASI seemed to be beneficial in stage III and stage IV melanoma when given in the adjuvant setting, while causing only very mild side effects.

KW - Active specific immunotherapy (ASI)

KW - Autologous tumor cell vaccines

KW - Delayed type hypersensitivity (DTH)

KW - Melanoma

KW - Metastasectomy

UR - http://www.scopus.com/inward/record.url?scp=0033798213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033798213&partnerID=8YFLogxK

U2 - 10.1023/A:1008363601515

DO - 10.1023/A:1008363601515

M3 - Article

C2 - 11038032

AN - SCOPUS:0033798213

VL - 11

SP - 965

EP - 970

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 8

ER -